MANNKIND CORP Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Fair Value
MANNKIND CORP (MNKD) had Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Fair Value of $171.14 million as of 2024-12-31, per its 10-Q filed 2025-08-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Held-to-Maturity, Maturity › Debt Securities, Held-to-Maturity, Maturity, Allocated and Single Maturity Date, Fair Value
us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue · last filed 2025-08-06
- 2024-12-31: Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Fair Value $171.14M.
- 2024-09-30: Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Fair Value $248.55M.
- 2024-06-30: Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Fair Value $244.92M.
- 2024-03-31: Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Fair Value $245.74M.
| Period end | Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, Fair Value |
|---|---|
| 2024-12-31 | $171.14M 10-Q · filed 2025-08-06 |
| 2024-09-30 | $248.55M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $244.92M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $245.74M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $122.57M 10-K · filed 2025-02-26 |
| 2023-09-30 | $129.86M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $135.12M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $154.81M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $158.92M 10-K · filed 2024-02-27 |
| 2021-12-31 | $160.10M 10-K · filed 2023-02-23 |
| 2020-12-31 | $59.49M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |